RECOVERY: COVID-19 Kaletra
In patients admitted to hospital with COVID-19, does Lopinavir-ritonavir therapy (Kaletra) compared to usual care, reduce 28-day mortality?
Continue reading »Tag: Pneumonia
RECOVERY: COVID-19 dexamethasone
In hospitalised patients with SARS-CoV-2 infection does dexamethasone in additional to usual care, compared to usual care alone, reduce 28-day mortality?
Continue reading »Boulware
In people who have high-risk or moderate-risk exposure to someone with confirmed COVID-19 infection, does taking hydroxychloroquine following the exposure compared to placebo reduce the incidence of a new illness compatible with COVID-19?
Continue reading »LEAP2
Is 5-day oral lefamulin non-inferior to 7-day oral moxifloxacin in the management of community-acquired bacterial pneumonia?
Continue reading »ANTHARTIC
Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest Francois et al. N Engl J Med 2019;381:1831-42. DOI: 10.1056/NEJMoa1812379 Clinical Question In post out-of-hospital cardiac arrest patients treated with targeted temperature management, does the use of empirical antibiotics prevent early ventilator-associated pneumonia? Background Rates of survival to hospital discharge and good neurological outcomes post out-of-hospital cardiac arrest (OOHCA) remain poor Despite […]
Continue reading »IPHIVAP
In adult mechanically ventilated patients, does inhaled heparin compared to inhaled saline or usual care reduce the incidence of ventilator acquired pneumonia (VAP)?
Continue reading »Uranga
In hospitalised patients with community-acquired pneumonia (CAP), is five days of antibiotic therapy non-inferior to standard practice with respect to clinical improvement?
Continue reading »Torres
In patients with severe community-acquired pneumonia and high inflammatory response, does the use of corticosteroids compared to placebo improve outcom
Continue reading »